Basilea Pharmaceutica (XSWX:BSLN) Long-Term Debt : CHF95.5 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Basilea Pharmaceutica Long-Term Debt?

Basilea Pharmaceutica's Long-Term Debt for the quarter that ended in Dec. 2023 was CHF95.5 Mil.

Basilea Pharmaceutica's quarterly Long-Term Debt declined from Dec. 2022 (CHF131.4 Mil) to Jun. 2023 (CHF113.2 Mil) and declined from Jun. 2023 (CHF113.2 Mil) to Dec. 2023 (CHF95.5 Mil).

Basilea Pharmaceutica's annual Long-Term Debt increased from Dec. 2021 (CHF94.5 Mil) to Dec. 2022 (CHF131.4 Mil) but then declined from Dec. 2022 (CHF131.4 Mil) to Dec. 2023 (CHF95.5 Mil).

Basilea Pharmaceutica Long-Term Debt Historical Data

The historical data trend for Basilea Pharmaceutica's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Long-Term Debt Chart

Basilea Pharmaceutica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

197.74

239.67

94.54

131.36

95.46

Basilea Pharmaceutica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Debt	Get a 7-Day Free Trial															94.54	94.77	131.36	113.18	95.46

Basilea Pharmaceutica (XSWX:BSLN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Basilea Pharmaceutica Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Basilea Pharmaceutica (XSWX:BSLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (XSWX:BSLN) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

BSLNz:UK

Address

Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058

Website

https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (XSWX:BSLN) Headlines

No Headlines